%0 Journal Article
%A Mai, E. K.
%A Bertsch, U.
%A Dürig, J.
%A Kunz, C.
%A Haenel, M.
%A Blau, I. W.
%A Munder, M.
%A Jauch, A.
%A Schurich, B.
%A Hielscher, T.
%A Merz, M.
%A Huegle-Doerr, B.
%A Seckinger, A.
%A Hose, D.
%A Hillengass, J.
%A Raab, M. S.
%A Neben, K.
%A Lindemann, H-W
%A Zeis, M.
%A Gerecke, C.
%A Schmidt-Wolf, I. G. H.
%A Weisel, K.
%A Scheid, C.
%A Salwender, H.
%A Goldschmidt, H.
%T Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
%J Leukemia
%V 29
%N 8
%@ 1476-5551
%C Basingstoke
%I Nature Publ. Group
%M DKFZ-2017-03074
%P 1721 - 1729
%D 2015
%X We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (⩾VGPR) in 504 newly diagnosed, transplant-eligible multiple myeloma patients. VCD was found to be non-inferior to PAd with respect to ⩾VGPR rates (37.0 versus 34.3
%K Boronic Acids (NLM Chemicals)
%K Pyrazines (NLM Chemicals)
%K Bortezomib (NLM Chemicals)
%K Dexamethasone (NLM Chemicals)
%K Doxorubicin (NLM Chemicals)
%K Cyclophosphamide (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:25787915
%R 10.1038/leu.2015.80
%U https://inrepo02.dkfz.de/record/127048